President Biden this week gave a speech promoting his Cancer Moonshot initiative and a new government health agency that he says will drive treatment breakthroughs. As usual, he gave no credit to drug makers that are producing game-changing treatments such as Amgen’s Lumakras for lung cancer.

Lung cancer kills more Americans than any other cancer. The five-year survival rate is a mere 18.6% and 5% for advanced forms. Treatments targeting particular protein or gene mutations have improved survival odds for breast, melanoma and some other cancers. But cancers driven by a mutation in the KRAS gene have eluded these breakthroughs, and lung cancer is one of them.